Gamma polyglutamated tetrahydrofolates and uses thereof

Patent metadata

Field	Value
Publication number	US-12048766-B2
Application number	US-201916967203-A
Country	US
Kind code	B2
Filing date	Feb 7, 2019
Priority date	Feb 14, 2018
Publication date	Jul 30, 2024
Grant date	Jul 30, 2024

Abstract

The disclosure relates generally to gamma polyglutamated tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated tetrahydrofolate, and methods of making and using the gamma polyglutamated tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).

First claim

What is claimed is:

1. A liposomal composition comprising a gamma polyglutamated tetrahydrofolate encapsulated by a liposome, wherein the liposome comprises a gamma polyglutamated tetrahydrofolate containing 4, 5, 2-10, 4-6, or more than 5, glutamyl groups, and wherein the liposome is pegylated and does not contain a targeting moiety having specific affinity for a surface antigen on a target cell.

2. The liposomal composition of claim 1 , wherein the gamma polyglutamated tetrahydrofolate is selected from the group consisting of:
(a) polyglutamated 5-formyl-THF;
(b) polyglutamated 10-formyl-THF;
(c) polyglutamated 5,10-methenyl-THF;
(d) polyglutamated 5-methyl-THF;
(e) polyglutamated tetrahydrofolate;
(f) polyglutamated 5,10-methylene-THF; and
(g) polyglutamated 5-formimino-THF.

3. The liposomal composition of claim 1 , wherein
(a) the gamma polyglutamated tetrahydrofolate comprises two or more glutamyl groups in the L-form having gamma carboxyl group linkages,
(b) each of the glutamyl groups of the gamma polyglutamated tetrahydrofolate is in the L-form and has a gamma carboxyl group linkage,
(c) at least one of the glutamyl groups of the gamma polyglutamated tetrahydrofolate is in the D-form and has a gamma carboxyl group linkage,
(d) each of the glutamyl groups of the gamma polyglutamated tetrahydrofolate other than the glutamyl group of tetrahydrofolate is in the D-form and has a gamma carboxyl group linkage, or
(e) the gamma polyglutamated tetrahydrofolate comprises two or more glutamyl groups in the L-form and at least one glutamyl group in the D-form having gamma carboxyl group linkages.

4. The liposomal composition of claim 1 , wherein the liposome comprises a gamma polyglutamated tetrahydrofolate containing 4-6 glutamyl groups.

5. The liposomal composition of claim 1 , wherein the liposome comprises a gamma tetraglutamated tetrahydrofolate.

6. The liposomal composition of claim 1 , wherein the liposome comprises a gamma pentaglutamated tetrahydrofolate.

7. The liposomal composition of claim 1 , wherein the liposome comprises a gamma hexaglutamated tetrahydrofolate.

8. The liposomal composition of claim 1 , wherein the liposome has a diameter in the range of 20 nm to 500 nm, 20 nm to 200 nm, or 80 nm to 120 nm.

9. The liposomal composition of claim 1 , wherein the liposome is formed from liposomal components comprising:
at least one of an anionic lipid and a neutral lipid;
at least one selected from: DSPE; DSPE-PEG; DSPE-PEG-maleimide; HSPC; HSPC-PEG; cholesterol; cholesterol-PEG; and cholesterol-maleimide; or
at least one selected from: DSPE; DSPE-PEG; DSPE-PEG-FITC; DSPE-PEG-maleimide; cholesterol; and HSPC.

10. The liposomal composition of claim 9 , wherein one or more liposomal components further comprises at least one steric stabilizer selected from: polyethylene glycol; poly-L-lysine; monosialoganglioside; poly(vinyl pyrrolidone); poly(acrylamide); poly(2-methyl-2-oxazoline); poly(2-ethyl-2-oxazoline); phosphatidyl polyglycerol; poly[N-(2-hydroxypropyl) methacrylamide]; amphiphilic poly-N-vinylpyrrolidones; L amino-acid-based polymer; oligoglycerol, copolymer containing polyethylene glycol and polypropylene oxide, Poloxamer 188, and polyvinyl alcohol.

11. The liposomal composition of claim 10 , wherein the steric stabilizer is polyethylene glycol and the polyethylene glycol has a number average molecular weight (Mn) of 200 to 5000 daltons.

12. The liposomal composition of claim 1 , wherein the liposome is anionic or neutral.

13. The liposomal composition of claim 12 , wherein the liposome has a zeta potential that is less than or equal to zero, between 0 to −150 mV, or between −30 to −50 mV.

14. The liposomal composition of claim 1 , wherein the liposome is cationic.

15. The liposomal composition of claim 1 , wherein the liposome has an interior space comprising the gamma polyglutamated tetrahydrofolate and an aqueous pharmaceutically acceptable carrier comprising:
a tonicity agent at a concentration of greater than 1%;
1% to 50% trehalose;
1% to 50% dextrose;
5% dextrose suspended in an HEPES buffered solution; or
a total concentration of sodium acetate and calcium acetate of between 50 mM to 500 mM.

16. The liposomal composition of claim 15 , wherein the interior space of the liposome has a pH of 5-8 or a pH of 6-7, or any range therein between.

17. The liposomal composition of claim 1 , wherein the liposome comprises less than 500,000 less than 200,000, or between 10 to 100,000 molecules of the gamma polyglutamated tetrahydrofolate, or any range therein between.

18. The liposomal composition of claim 1 , further comprising one or more of an immunostimulatory agent, a detectable marker and a maleimide, wherein the immunostimulatory agent, the detectable marker or the maleimide is attached to polyethylene glycol (PEG) or the exterior of the liposome.

19. The liposomal composition of claim 18 , wherein the immunostimulatory agent is at least one selected from the group consisting of: a fluorescein; a fluorescein isothiocyanate (FITC); a DNP; a beta glucan; a beta-1,3-glucan; a beta-1,6-glucan; a resolvin; and a Toll-like receptor (TLR) modulating agent, and an eritoran lipid.

20. The liposomal composition of claim 1 , which further comprises at least one cryoprotectant selected from mannitol, trehalose, sorbitol, and sucrose.

21. The liposomal composition of claim 1 , which further comprises fluoracil or methotrexate.

22. A pharmaceutical composition comprising the liposomal gamma composition of claim 1 .

23. A method of killing a hyperproliferative cell that comprises contacting a hyperproliferative cell with the liposomal composition of claim 1 .

24. A method for treating cancer that comprises administering an effective amount of the liposomal composition of claim 1 to a subject having cancer.

25. A method of preparing a gamma polyglutamated tetrahydrofolate composition comprising the liposomal composition of claim 1 , the method comprising: forming a mixture comprising: liposomal components and gamma polyglutamated tetrahydrofolate in solution; homogenizing the mixture to form liposomes in the solution; and processing the mixture to form liposomes containing gamma polyglutamated tetrahydrofolate.

26. The liposomal composition of claim 1 , wherein the gamma polyglutamated tetrahydrofolate is gamma polyglutamated THF.

27. The liposomal composition of claim 1 , wherein the gamma polyglutamated tetrahydrofolate is gamma polyglutamated 10-formyl-THF.

28. The liposomal composition of claim 1 , wherein the gamma polyglutamated tetrahydrofolate is gamma polyglutamated [6R]-10-formyl-THF.

29. The liposomal composition of claim 1 , wherein the gamma polyglutamated tetrahydrofolate is gamma polyglutamated 5,10-methylene-THF.

30. The liposomal composition of claim 1 , wherein the gamma polyglutamated tetrahydrofolate is gamma polyglutamated [6R]-5,10-methylene-THF.

31. The liposomal composition of claim 1 , wherein the gamma polyglutamated tetrahydrofolate is gamma polyglutamated 5-methyl-THF.

32. The liposomal composition of claim 1 , wherein the gamma polyglutamated tetrahydrofolate is polyglutamated [6S]-5-methyl-THF.

33. The liposomal composition of claim 1 , wherein the liposome comprises at least 2 gamma polyglutamated tet

Assignees

• L E A F Holdings Group Llc

Inventors

• Niyikiza Clet
• Moyo Victor Mandla

Classifications

• A61K49/0054

  Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title